Xenetic Biosciences (NASDAQ:XBIO) Releases Earnings Results

Xenetic Biosciences (NASDAQ:XBIO) posted its quarterly earnings results on Thursday. The company reported ($0.41) earnings per share (EPS) for the quarter, FiscalAI reports. Xenetic Biosciences had a negative return on equity of 39.28% and a negative net margin of 70.03%.The business had revenue of $0.66 million during the quarter.

Xenetic Biosciences Trading Up 11.2%

XBIO opened at $3.17 on Friday. Xenetic Biosciences has a twelve month low of $1.90 and a twelve month high of $13.93. The stock has a market cap of $7.26 million, a PE ratio of -2.64 and a beta of 2.10. The business’s 50 day moving average is $2.89 and its 200-day moving average is $2.81.

Analyst Ratings Changes

Separately, Weiss Ratings restated a “sell (d-)” rating on shares of Xenetic Biosciences in a research note on Friday, July 17th. One equities research analyst has rated the stock with a Sell rating, According to data from MarketBeat.com, the company currently has a consensus rating of “Sell”.

Hedge Funds Weigh In On Xenetic Biosciences

A hedge fund recently bought a new stake in Xenetic Biosciences stock. DRW Securities LLC bought a new position in Xenetic Biosciences, Inc. (NASDAQ:XBIO) during the fourth quarter, according to its most recent filing with the Securities and Exchange Commission. The fund bought 13,824 shares of the company’s stock, valued at approximately $30,000. DRW Securities LLC owned approximately 0.60% of Xenetic Biosciences at the end of the most recent reporting period. Hedge funds and other institutional investors own 15.12% of the company’s stock.

About Xenetic Biosciences

Xenetic Biosciences, Inc is a clinical-stage biotechnology company focused on the development and commercialization of enhanced protein and peptide therapeutics for oncology, immunology and rare diseases. The company leverages its proprietary platforms to extend the half-life, improve the stability and optimize the delivery of biopharmaceuticals. Xenetic’s pipeline includes novel candidates designed to address unmet medical needs in solid tumors and inherited disorders.

At the heart of Xenetic’s technology portfolio are two complementary platforms: PolyXen, which employs a unique polysialylation process to prolong drug circulation and reduce immunogenicity, and Alphabody, a next-generation antibody-mimetic framework engineered for high-affinity binding to challenging targets.